Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Inclusion Criteria: * Be ≥18 years of age. * Have a histopathological diagnosis (fresh or banked tumor biopsy sample, preferably collected within the last 3 years) of an advanced solid tumor for which curative treatment is not available and have undergone appropriate standard of care treatment options (in the opinion of the treating investigator). * Have a documented IDH1 gene-mutated disease (from a fresh tumor biopsy or the most recent banked tumor tissue available) based on CLIA certified sequencing (R132C/L/G/H/S mutation variants tested). * For glioma, must have both 1) contrast enhancing disease and 2) WHO 2016 grade II * Have an ECOG PS score of 0 or 1 (Appendix 11.1) * Have at least one evaluable and measurable lesion as defined by RECIST v1.1 (solid tumors) or Response Assessment in Neuro-Oncology (RANO) Criteria (glioma). * Have recovered from toxicities associated with prior anticancer therapy to baseline or ≤ grade 1 unless stabilized under medical management per investigator. * Have adequate bone marrow function as evidenced by: * Absolute neutrophil count ≥ 1,500/mm3 or 1.5 × 109/L * Hemoglobin ≥ 8 g/dL * Platelets ≥ 100,000/mm3 or 100 × 109/L * Have adequate hepatic function as evidenced by: * Serum total bilirubin ≤ 2 × upper limit of normal (ULN), unless considered due to Gilbert's disease * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN in the presence of liver metastases (or primary hepatic tumor) OR ≤ 2× ULN w…